Utama › Leukemia Limfositik Kronik › Mississippi
Kajian klinikal Leukemia Limfositik Kronik di Mississippi
5 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi di Mississippi.
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven
Mengambil pesertaFasa 3
Umur 65 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07321652Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus
- Baptist Cancer Center-Grenada, Grenada
- Baptist Memorial Hospital and Cancer Center-Union County, New Albany
- dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT04269902A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Hattiesburg Clinic Hematology/Oncology ( Site 5416), Hattiesburg
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT05947851A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Gulfport Memorial Hospital, Gulfport
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Mei 2026 · NCT06588478Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Hattiesburg Clinic /ID# 233443, Hattiesburg
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Feb 2026 · NCT04895436Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.